A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This study tests a CAR-T cell therapy called C-CAR168 for people with severe autoimmune diseases that have not responded to standard treatments. CAR-T therapy reprograms immune cells to reduce harmful immune activity. The diseases targeted include lupus, multiple sclerosis, myasthenia gravis, and other serious autoimmune conditions. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with lupus (SLE), immune-mediated necrotizing myopathy, neuromyelitis optica, multiple sclerosis, myasthenia gravis, or systemic sclerosis for at least 6 months - Your disease remains active or has relapsed despite at least two immunosuppressant treatments - Your organ function is adequate **You may NOT be eligible if...** - You have active hepatitis B, hepatitis C, or HIV infection - You have had recent serious infections - You have certain cancers or conditions that would make CAR-T therapy unsafe - Your disease has not been formally diagnosed for at least 6 months Talk to your doctor to see if this trial is right for you.